Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
CLOZAPINE
MYLAN PHARMACEUTICALS ULC
N05AH02
CLOZAPINE
50MG
SUSPENSION
CLOZAPINE 50MG
ORAL
125ML
Prescription
ATYPICAL ANTIPSYCHOTICS
Active ingredient group (AIG) number: 0122583003; AHFS:
CANCELLED PRE MARKET
2019-09-30
_Page 1 of 58_ PRODUCT MONOGRAPH PR GEN-CLOZAPINE Clozapine Tablets 25 mg, 50 mg, 100 mg and 200 mg Pharmaceutical Standard: Mylan Std. Clozapine Oral Suspension 50 mg/ml Antipsychotic Agent Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Date of Revision: April 16, 2019 Submission Control No.: 226604 _Page 2 of 58_ PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................. 3 SUMMARY PRODUCT INFORMATION .................................................................................................. 3 INDICATIONS AND CLINICAL USE ....................................................................................................... 4 CONTRAINDICATIONS ............................................................................................................................. 5 WARNINGS AND PRECAUTIONS ........................................................................................................... 6 ADVERSE REACTIONS ........................................................................................................................... 20 DRUG INTERACTIONS............................................................................................................................ 27 DOSAGE AND ADMINISTRATION ....................................................................................................... 28 OVERDOSAGE .......................................................................................................................................... 32 ACTION AND CLINICAL PHARMACOLOGY ...................................................................................... 32 STORAGE AND STABILITY ................................................................................................................... 34 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................................... 34 PART II: SCIENTIFIC INFORMATION .......................................................... Prečítajte si celý dokument